Better Health for All

Travere Therapeutics focuses on developing and delivering life-changing therapies for rare diseases, including approved products like FILSPARI for IgAN and Thiola EC, and investigational therapies for Homocystinuria, indicating a strong positive health impact.

However, FILSPARI carries a BOXED WARNING for hepatotoxicity and embryo-fetal toxicity, with liver enzyme elevations observed in up to 3.5% of patients and common adverse reactions in ≥5% of patients. It is available only through a restricted REMS program requiring liver function monitoring. The company offers comprehensive patient assistance programs, including a $0 copay program for eligible commercially insured patients and free FILSPARI for up to 12 months for uninsured/underinsured patients. While these programs exist, there is no evidence of product pricing relative to production cost or the percentage of those in need reached by these programs, making a quantitative score for price accessibility impossible. The company actively reaches vulnerable populations, including pediatric patients in clinical trials and uninsured/underinsured individuals through patient assistance, with support available in multiple languages. While risks are disclosed through a BOXED WARNING and REMS, the high adverse event rates and contraindications indicate significant product risks. Travere Therapeutics conducts research and development for rare diseases, but specific investment percentages are not provided. The company demonstrates strong healthcare data responsibility, complying with EU-U.S. DPF Principles and implementing safeguards for personal data. It provides educational information about products and disease states via websites and Nurse Educators. Clinical trials are ongoing, with enrollment voluntarily paused in the HARMONY Study due to commercial manufacturing scale-up, and some trials involve children with parental consent.

Fair Pay & Worker Respect

In 2024, Travere Therapeutics' CEO-to-median employee pay ratio was 17:1.

As of January 31, 2025, no employees in the United States were represented by a labor union or covered by collective bargaining agreements. The company's latest employee engagement survey in November 2024 had an 84% response rate, and 66% of employees would recommend working there according to Glassdoor reviews. In December 2023, the company implemented an approximate 20% workforce reduction focused on non-field-based employees. There have been no significant labor law infractions in the past year.

Honest & Fair Business

Travere Therapeutics has a comprehensive Code of Business Conduct and Ethics that applies to all directors, officers, employees, and agents.

The company strictly prohibits retaliation against employees who report known or suspected violations in good faith. Employees can report issues through multiple channels, including an anonymous 24/7 Ethics Helpline. The company also has a policy prohibiting the use of funds or assets for unlawful or improper purposes, including bribes and kickbacks, and requires compliance with the Foreign Corrupt Practices Act. Additionally, the company states that conflicts of interest of directors, executive officers, or other principal officers may only be waived by the Board of Directors or the appropriate committee of the Board and will be promptly disclosed to the public.

Kind to Animals

Travere Therapeutics, Inc. conducts pre-clinical studies on animals, specifically mice, to assess drug safety.

No further information regarding the extent of animal testing, specific policies, alternative testing methods, or other animal welfare practices is available.

No War, No Weapons

Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases. Its core business, as evidenced by its financial reports and government contracts, involves pharmaceutical products such as Tiopronin Thiola and Thiola 100 Mg.

The company's NAICS code is 325412 (Pharmaceutical Preparation Manufacturing) and PSC code is 6505 (Drugs and Biologicals). Government contracts are with civilian agencies, specifically a VA Network Contracting Office. There is no evidence of any revenue derived from arms or defense contracts, involvement in dual-use technology with military applications, sales to embargoed regimes, or any other activities related to the defense sector. All provided metrics explicitly state 'Not applicable' in the context of defense contracting, indicating no involvement in such activities.

Planet-Friendly Business

The provided articles do not contain specific quantitative data for any of the Planet-Friendly Business KPIs. While general ESG risk ratings are mentioned, these do not provide the concrete metrics required by the rubric for scoring individual KPIs, such as total greenhouse gas emissions, renewable energy percentage, water use per revenue, or waste diversion rates.

All articles explicitly state a lack of quantitative data for the requested metrics.

Zero Waste & Sustainable Products

The company's product stewardship plan for unwanted medicine explicitly states it does not provide for the separation and recycling of packaging from covered drugs, indicating 0% sustainable packaging for these items.

Collected drugs are disposed of at permitted hazardous waste, municipal waste, or hospital/medical/infectious waste incinerators in accordance with all applicable laws and regulations, demonstrating compliant hazardous waste management.